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Abstract The diagnostic criteria for focal cortical dys-
plasia type I (FCD I) remain to be well and consistently
deﬁned. Cortical layer-speciﬁc markers (CLM) provide a
potential tool for the objective assessment of any dyslam-
ination. We studied expression patterns of recognised CLM
using immunohistochemistry for N200, ER81, Otx1,
Map1b (subsets of V/VI projection neurones), Pax6, Tbr1,
Tbr2 (differentially expressed in cortical neurones from
intermediate progenitor cells), Cux 1 (outer cortical layers)
and MASH1 (ventricular zone progenitors). Dysplasia
subtypes included FCD I and II, dysplasias adjacent to
hippocampal sclerosis (HS) or dysembryoplastic neuroep-
ithelial tumours (DNTs); all were compared to neonatal
and adult controls. Laminar expression patterns in normal
cortex were observed with Tbr1, Map1b, N200 and Otx1.
FCDI cases in younger patients were characterised by
abnormal expression in layer II for Tbr1 and Otx1. FCDII
showed distinct labelling of balloon cells (Pax6, ER81 and
Otx1) and dysmorphic neurones (Tbr 1, N200 and Map1b)
supporting origins from radial glia and intermediate pro-
genitor cells, respectively. In temporal lobe sclerosis cases
with dysplasia adjacent to HS, Tbr1 and Map1b highlighted
abnormal orientation of neurones in layer II. Dyslamination
was not conﬁrmed in the perilesional cortex of DNT with
CLM. Finally, immature cell types (Otx1, Pax6 and Tbr2)
were noted in varied pathologies. One possibility is acti-
vation of progenitor cell populations which could con-
tribute to the pathophysiology of these lesions.
Keywords Cortical layer markers  Dysplasia 
Epilepsy
Introduction
Following the revision to the classiﬁcation of focal cortical
dysplasias (FCD) in epilepsy in 2004 [41], there has been
improved consistency in the clinical, radiological and
pathological correlative data for the more severe types of
dysplasia (FCD II) characterised by abnormal cytomor-
phology [38]. The criteria for milder dysplasias (FCD I),
characterised mainly by abnormalities in cortical lamina-
tion, are less well deﬁned [7] and more open to subjective
interpretation with poor reproducibility shown between
observers [12]. Varied neocortical laminar abnormalities
are also reported adjacent to hippocampal sclerosis (HS)
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DOI 10.1007/s00401-010-0686-x[51] and glioneuronal tumours including dysembryoplastic
neuroepithelial tumours (DNT) [17, 50]. These dysplasias
are also less well deﬁned, including their distinction from
isolated FCD.
Cortical layer-speciﬁc markers (CLM) are a potential
diagnostic tool for the evaluation of mild dysplasias in
epilepsy [26]. CLM include transcription factors, cyto-
skeletal proteins and calcium-binding proteins which show
neuronal subtype and/or layer-speciﬁc expression patterns
reﬂecting ontogeny and cortical maturity. Largely studied
in the rodent cortex [26], there are few studies evaluating
these markers in human epilepsy tissues [24, 32]. CLM
expression is likely to vary between species, the stage of
cortical maturation, between cortical regions and with
neuronal activity, including seizures; these factors have to
be considered in their evaluation in human pathologies
[26].
Our aim was to assess a panel of CLM in the discrim-
ination of commonly encountered dysplasia subtypes in
epilepsy surgical tissue. We selected a panel shown by
previous studies of cortical development and maturation
demonstrated to reﬂect layer or neuronal lineage speciﬁcity
[26, 36]. Any abnormalities in their distribution might
enable a more accurate classiﬁcation of these disorders.
Materials and methods
Case selection and histopathological features
The study was approved by the respective ethics commit-
tees of the participating centres where informed consent
was obtained for the use of brain tissue and for access to
medical records for research purposes. All surgical cases
underwent therapeutic resection for refractory epilepsy and
the pathological tissue was surplus to diagnostic require-
ment. In all cases we selected larger resection specimens so
that adjacent normal cortex was more likely to be included.
We aimed to include cases involving the temporal neo-
cortex for all pathology groups where possible. The details
of cases, including main histological features, are outlined
in Table 1. Within groups similar dysplasia pathology
types were studied, including cases from previous pub-
lished series [28, 51]; 14 cases of FCD IA (henceforth
referred to as FCDI), 9 cases of FCD II B (henceforth
referred to as FCD II), 8 cases of dysplasia adjacent to
DNT, 5 cases of dysplasia associated with HS and temporal
lobe sclerosis (TLS) in addition to 14 control cases
including epilepsy controls (no dysplasia). We did not
include FCD type IB or IIA cases in the present study.
Table 1 Details of the cases and controls studied
Group Number of
cases
Age range Characteristic features of dysplasia Localisation of
tissue block
a
Nature
of tissue
Control groups
Paediatric 8 1 day–17 years No dysplasia Temporal (5)
Frontal (2)
Occipital (1)
PM
Adult 2 33–41 years No dysplasia Temporal (2) S
Epilepsy 4 6–49 years Hippocampal sclerosis only Temporal (4) S
Dysplasia groups
FCD type I [28] 14 2–28 years Columnar cortical architecture
Excess of white matter neurones
Temporal
a (9)
Frontal (4)
Occipital (1)
S
FCD type II 9 1–52 years Balloon cells
Dyslamination
Dysmorphic neurones
Temporal (4)
Frontal (5)
S
Dysplasia adjacent to HS
(TLS) [51]
5 27–47 years Clustering of neurons in layer
II and abnormal orientation.
Neuronal loss from layer II and III.
Temporal (5) S
Dysplasia adjacent to DNT 8 22–43 years Hypercellularity in layer I (7/8)
Dyslamination
Intracortical hamartias (5/8)
Temporal (5)
Frontal (2)
Unspeciﬁed site (1)
S
S surgical case, PM postmortem, FCD focal cortical dysplasia, DNT dysembryoplastic neuroepithelial tumour, TLS temporal lobe sclerosis
a In some of the FCD type I cases the pathology was multifocal, although only the temporal lobe from each case has been included in the present
study
518 Acta Neuropathol (2010) 120:517–528
123Immunohistochemistry
In all cases a single representative formalin-ﬁxed, parafﬁn-
embedded tissue block from each case was selected and
further sections cut at 7 lm thickness. Sections were
dewaxed and rehydrated, followed by blockage of endog-
enous peroxidase activity by 15 min incubation in 0.9%
hydrogen peroxide in de-ionised water. A panel of 9 CLM
antibodies was selected (as detailed in Table 2) in addition
to NeuN (1:100, Chemicon). After washing, the sections
were microwaved 12 or 15 min in antigen retrieval solu-
tion, then cooled for 20 min. Staining was visualised with
diaminobenzidine (DAB) and NovaRed for N200 antibody.
Sections where DAB was applied were then enhanced in
copper sulphate, and counterstained with haematoxylin.
Between each step, sections were washed in phosphate
buffer saline with 0.05% Tween 20 (PBS?T). Negative
controls were treated identically except that the primary
antibody was omitted. For some of the antibodies with
developmental regulation, e.g. Pax6, Tbr2, sections of
foetal brain including the VZ and SVZ (20–36 gestational
weeks) were used as a positive control. The laminar
staining pattern with each CLM in all cases was assessed
through comparison to the corresponding NeuN-stained
section (Fig. 1a).
Immunoﬂuorescence
Cases were selected for double labelling immunoﬂuores-
cence using combinations of NeuN, GFAP, CD68 CD34,
calretinin with CLM, following the initial observations
with immunohistochemistry. 7 lm sections were dewaxed
and rehydrated and washed in water. Endogenous peroxi-
dase was quenched with 3% hydrogen peroxide and
de-ionised water. Sections were microwaved in antigen
retrieval buffer. Protein blocking was carried out with
normal horse serum followed by incubation of primary
antibodies overnight at 4C. Sections were washed and
Table 2 Details of cortical layer marker panel for immunohistochemistry
Antibody Source Antibody
dilution
Rationale for inclusion References
Tbr1 (T-box-brain-gene) Gift form Dr. R. Hevner
a Polyclonal
1:4,000
Expressed in cortical neurones derived from
IPC cell lineages
IPC have a role in cytoarchitectural regional
organisation
[30, 43]
Tbr2 (T-box-brain-gene) Gift from Dr. R. Hevner
a Polyclonal
1:1,500
Expressed in IPCs or basal progenitors in the
SVZ
[20, 27]
Pax6 (Paired box 6) Santa Cruz Biotechnology,
Inc., CA, USA
Polyclonal
1:100
Expressed in apical progenitors in the VZ
(radial glial stem cells)
Largely conﬁned to the VZ and SVZ from
10 to 17 weeks gestation
[5]
Map1b (Microtubule
associated protein type 1b)
Abcam, Cambridge, UK Monocloncal
1:2,500
Earliest MAP expressed during development
Identiﬁes a subset of layer V neurones in
foetal neocortex with expression retained
in adult neocortex
[46, 26, 14]
N200 (Neuroﬁlament heavy chain) Sigma–Aldrich, Saint Louis,
Missouri, USA
Polyclonal
1:3,000
Expressed in projection neurones in layer II,
III, V and VI. Highlights selective non-
cortical projecting populations within layer
V neurones
[35]
Otx1 (Orthodenticle homolog 1) Abcam, Cambridge, UK Polyclonal
1:100
Expressed in a subset of layer V/VI
projection neurones
[27, 35]
ER81 (ETS transcription factor) Abcam, Cambridge, UK Polyclonal
1:6,000
Highlights a subset of layer V projection
pyramidal neurones in rodents and
primates as well as in the developing
human neocortex
[5]
Cux1 (Homeobox cut gene 1); Abcam, Cambridge, UK Monoclonal
1:2,000
Localises to the superﬁcial cortex, layer II–
IV in rodent cortex
[2, 39]
MASH1 (Mammalian achaete-
scute homolog-1, or Ascl1)
Abcam, Cambridge, UK Polyclonal
1:200
A helix–loop–helix transcription factor
expressed in basal progenitors in the VZ,
promoting progenitor cell maturation
[8, 32]
IPC intermediate migrating progenitor cell, VZ ventricular zone, SVZ subventricular zone
a Dr R Hevner’s Laboratory, Seattle Children’s Hospital Research Institute, Seattle, WA, USA
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123Fig. 1 Controls. a Adult control: NeuN labelling in temporal lobe
demonstrating distinct cortical laminae. b Adult control: Map1b
showing cytoplasmic labelling in layers II, III, V (arrowed) and VI
pyramidal cells with an absence of labelling in mid layers. c Adult
control: N200 with labelling of isolated pyramidal cells mainly in
layer V and VI and to a lesser extent the upper cortical layers
(arrows). d Adult control: Tbr1 with nuclear labelling of a proportion
of neurones in all cortical layers particularly IV, V and VI. e Paediatric
control (day 1): Otx1 with frequent cells visible throughout the cortex
but more prominent in layers II and IV. f Tbr2 frequent cytoplasmic
labelling of multipolar cells through the white matter were observed
in neonatal period. (inset double labelling for Tbr2 and GFAP
showing co-localisation in some white matter cells GFAP green,
Tbr2 red). g Map1b staining of the same case as in f labelled only
occasional cells in cortical layer V at 1 day in contrast to the
hippocampus which showed numerous Map1b-positive cells. h Pax6:
nuclear labelling of small cells in the periventricular white matter in
neonate (inset ER81, nuclear labelling of pyramidal cells and a subset
of satellite cells). i Tbr1 staining at 2 years conﬁrming nuclear
labelling in proportion of layer V neurones. j Otx1 layer II in adult
epilepsy control showing frequent cytoplasmic labelling of small,
cells with immature morphology. Bars f, g, i 30 lm; h, j 45 lm,
a–e cortical panoramas representing layers I–VI, taken at original
magniﬁcation (910 objective) and rescaled to align layers
520 Acta Neuropathol (2010) 120:517–528
123incubated with secondary anti-rabbit ImmPRESS (Vector
Laboratories) for polyclonal antibodies followed by Cy3,
or ﬂuorescein tyramide signal ampliﬁcation (PerkinElmer
Life and Analytical Sciences, Boston, MA). Sections then
were washed and quenched in 1% hydrogen peroxide in
PBS for 20 min in order to prevent any deposited tyramide
combining with the second tyramide signal that followed.
The sections were incubated with anti-mouse ImmPRESS
(Vector Laboratories) for monoclonal antibodies followed
by CY3 or ﬂuorescein tyramide with dilutions for mono-
clonal GFAP (Dako, 1:30), polyclonal GFAP (Dako;
1:300), and polyclonal Calretinin (1:2,000; Swant, Bellin-
zona, Switzerland). Alexa Fluor chicken anti-rabbit 594,
(1:100) and goat anti-mouse 488, (1:70) (Molecular Probe;
Eugene, OR, USA) was used. After each step, sections
were washed in PBS. Sections were mounted on Vecta-
shield with DAPI (Vector Laboratories) and visualised with
a Zeiss LSM 510 Meta or Leica confocal laser microscope.
Results
Controls
CLM expression for control cases is summarized in
Table 3 (Fig. 1). The most distinct lamina-speciﬁc
expression patterns were noted for Map1b (layers V–VI
and II), N200 (layers V–VI) and Tbr1 (layers IV–VI)
(Fig. 1b–d). For three CLM (N200, Map1b, Tbr1) pro-
gressively greater intensity and frequency of cortical
neuronal staining was noted in older children and adults
compared to infant controls (Fig. 1b, g). In a further three
CLM (Otx1, Tbr2, Cux1) the expression reduced with
cortical maturation (Fig. 1e, f) and in three (Mash1, ER81,
Pax6) no obvious difference was noted between age groups
(Fig. 1h and inset). Immature cell types, some with bipolar
or multipolar processes were noted with Tbr2, Pax6, Otx1
particularly in paediatric cases (Fig. 1e, f). In epilepsy
controls without dysplasia, enhanced labelling with Otx1
and Tbr2 was noted compared to non-epilepsy controls
(Table 3; Fig. 1j).
Cortical dysplasias
The patterns of CLM expression speciﬁc to each dysplasia
type are summarized below (and in Table 4). All markers
were studied for each pathology but only detailed where
they deviated from control ﬁndings.
FCD I
A striking ﬁnding in six cases (between 2 and 6 years of
age) was intense nuclear labelling of small cells at the
Table 3 Summary of the main laminar staining patterns with anti-
body panel in control tissues
Layer Paediatric
control (no
epilepsy)
Adult control
(no epilepsy)
Epilepsy (no MCD)
(where different
from non-epilepsy
controls)
I Tbr2 (M
a) ER81 (A) Otx1 (I)
ER81 (A) Cux 1 (N) Tbr2 (M)
Cux 1 (I, M) Pax6 (I)
MASH1 (P)
II Otx 1 (I) Tbr1 (A) Otx 1 (I, S)
Cux 1 (N) Map1b (P) Tbr2 ± (I, M)
ER81 (A) N200 ± (P)
ER81 (A)
Cux1 (N)
III ER81 (A) Tbr1 (P) Otx 1 (I, S)
Map1b (P) Map1b (P)
N200 ± (P)
ER81 (A)
Cux1 (N)
IV Map1b ± (N) Tbr1 (N) Otx 1 (I, S)
Otx1 (I) ER81 (A)
Cux 1 (N) Cux1 (N)
ER81 (A)
V Tbr1 ± (P) Tbr1 (P) Otx 1 (I, S)
Map1b ± (P) Map1b (P)
N200 ± (P) N200 (P)
ER81 (A) ER81 (A)
MASH1 ± (P) Cux1 (N)
VI Tbr1 (P) Tbr1 (P) Otx 1 (I, S)
Map1b ± (P) Map1b (P)
N200 ± (P) N200 (P)
ER81 (A) ER81 (A, S)
Otx 1 (I) Cux1 (N)
MASH1 ± (P)
White matter Tbr1 (I) Tbr1 (A) Otx 1 (I, S)
Tbr2 (M
a) N200 (P)
Otx1 (I) Map1b ± (A)
ER81 (A) ER81 (A)
Cux 1 (I) Pax6 (I)
MASH1 ± (P) Cux 1 (N)
Pax6 (I) MASH1 ± (P)
For the epilepsy control group markers are listed only where they
deviated from other control groups. Markers underlined indicate more
intense and frequent labelling of cells in the corresponding lamina
MCD malformation of cortical development, ± indicates less fre-
quent cells were seen to label, P pyramidal cell, N non-pyramidal
cell, A all types of mature neuronal cells, i.e. pyramidal and non-
pyramidal, M small, multipolar cell with staining of cytoplasmic
processes, including bipolar cells, I immature small cell of indeter-
minate lineage (small nucleus with little cytoplasm), S perineuronal
satellite cells
a Co-expression with GFAP shown in controls in some populations
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123interface of layer I and II with Tbr1 (Fig. 2a). Similar cells
also labelled with Otx1 (Fig. 2b). Occasional cells with
multipolar processes were noted with Tbr2, scattered in
both the upper cortical layers and white matter. These cells
were not clearly identiﬁed on conventional stained sections
and cells of a similar immunophenotype were not seen in
older FCDI cases (6–28 years). Enhanced labelling of
small cells at the interface of layer I and II was also noted
Table 4 Summary of main positive ﬁndings with cortical layer markers in dysplasia types in epilepsy surgical pathologies
Pathology
group
Cell types/pathology
feature
Expression of cortical layer markers Cortical layer Hypothesis of origin based
on immunophenotype
FCD I Immature cells Tbr1, Pax6, Otx1 Layer I/II interface Immature layer II cells
Columnar alignment Highlighted by Map1b Layers II–IV mainly Abnormal maturation (mid-
cortical layers)
FCD II Balloon cells Pax6, Otx1, ER81,
Cux1  Tbr2
White matter and layer I
mainly
Derived from radial glia/IPC
transitional cell type
Dysmorphic neurones Map1b[Tbr1 N200[Otx1
ER81, MASH1
All cortical layers, except
layer I
Resemble mature cortical
neurones; derived from IPC
TLS Neuronal clustering and
mal-orientation
Map1b, Tbr1,[Otx1, Tbr2,
Pax6
Layer II (superﬁcial
border)
Selective re-organisation of mature
layer II neurones
DNT Neurones in
glioneuronal
element
Map1b Layers II, III, IV and VI Entrapped normal cortical
neurones N200 V, VI[II, III
Tbr1 IV–VI
Adjacent cortex layer I
hypercellularity
ER81, Cux1[Otx1, Pax6[Tbr2,
N200.
Layer I Similar to tumour OLC: origins
from residual layer I progenitor
cells (‘secondary germinal
matrix’) rather than IPCs.
DNT dysembryoplastic neuroepithelial tumour, TLS temporal lobe sclerosis, OLC oligodendrocyte-like cell, IPC intermediate progenitor cells
Fig. 2 Focal cortical dysplasia (type Ia). a Tbr1 nuclear labelling of
small, immature appearing cells localised to the interface of layer I
and II (arrowhead); similar cells are shown at higher magniﬁcation
from another FCDI case in the inset. b Otx1 labelling of cells at the
interface of layer I and II with extension of cytoplasmic processes into
layer I (shown at higher magniﬁcation in inset). c Double labelling
with Pax6 and GFAP in layer I conﬁrmed co-localisation in a
proportion of cells. d Map1b the small immature cells in layer II are
negative (arrowed) compared to the positive mature pyramidal cells.
e Map1b in another case conﬁrming expansion of labelling in upper
compared to lower cortical layers. Bars in a, b 30 lm, c 20 lm,
d 10 lm, e 500 lm
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123with Pax6 (Fig. 2c); confocal imaging conﬁrmed co-
localisation of a proportion with GFAP (Fig. 2c) but not
NeuN. In eight cases, labelling of pyramidal neurons for
Map1b in layers II–III (Fig. 2d) was greater than in deeper
cortical layers, giving the impression of expansion of the
superﬁcial cortical layers (Fig. 2e) compared to controls.
The Map1b-positive pyramidal neurons remained normally
orientated. In regions with enhanced columnar architecture,
this organisational pattern was enhanced on Map1b stain-
ing with sheaths of perpendicular dendrites separating
columns of neurons in the mid-cortical layers.
FCD II
Dysmorphic neurones (DN) and balloon cells (BC) showed
distinct CLM expression patterns regardless of laminar
location. DN were present through all cortical layers except
layer I and showed variable immunopositivity with Tbr1
(Fig. 3a) but more frequently with Map1b and N200
(Fig. 3b).Cytoplasmic,perinuclearoroccasionalintranuclear
labelling patterns for Otx1 in DN was observed (Fig. 3c).
Weak tostrong cytoplasmic labelling of DNfor MASH1was
observed (Fig. 3d), although many were not labelled.
BC, including those located in the white matter and
layer I, showed variability of staining with Tbr2 both
within and between cases. Strong nuclear labelling of BC
was noted for Pax6 in four cases, with co-localisation with
GFAP but not NeuN (Fig. 3e). Labelling of the cytoplasm
of BC for Otx1 was striking in the majority of cases,
highlighting multipolar cellular processes (Fig. 4f). There
was co-expression of Otx1 with GFAP and CD34 (Fig. 3g)
in a proportion of BC. BC in the white matter or layer I also
showed intense nuclear positivity for ER81 (Fig. 3h) in
contrast to DN which were more weakly labelled. The
majority of BC were Cux1 positive compared to a near
absence of labelling of DN with Cux1. In addition, intra-
cortical cytoplasmic labelling of multipolar cells and small
immature intracortical cells was noted with Tbr2 and Otx1,
as in epilepsy controls.
Dysplasia adjacent to hippocampal sclerosis
[temporal lobe sclerosis (TLS)]
These cases all showed neuronal loss in the supragranular
cortex and re-organisational dysplasia of neurons in layer II
as previously described [51]. With CLM residual clusters
Fig. 3 Focal cortical dysplasia type IIB. a Tbr1 moderate labelling of
the cytoplasm of dysplastic neurones was observed (arrowhead)
compared to negative labelling of other dysplastic cells in proximity
(arrow) and strong intensity of interspersed normal neuronal nuclei.
b N200 positive labelling of dysmorphic neurones. c Otx1 dysmorphic
neurones showing diffuse cytoplasmic positivity and occasional
intranuclear inclusions (top-right inset) and perinuclear labelling
(bottom-left inset). d Mash1 weak cytoplasmic labelling of dysmor-
phic neurones is observed in this case. e Pax6 co-localisation with
GFAP in balloon cells including a multinucleated balloon cell
(arrowed). f Otx1 balloon cell showing strong cytoplasmic positivity
and multipolar processes. g Otx1 co-localisation with CD34 in a
balloon cell. h ER81 strong nuclear staining of balloon cells is
observed. Bars a–d, h 20 lm; e, f 10 lm; g 30 lm
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123of neurons in layer II in many regions showed intense
labelling with Tbr1 (Fig. 4a, c) and Map1b (Fig. 4b, d)
highlighting their abnormal, horizontal orientation. Double
labelling for calretinin, which labels a subset of fusiform
inhibitory interneurones that predominate in upper cortical
layers, and Map1b showed that there appeared to be
selective mal-alignment of the Map1b-positive cells
(Fig. 4e). In addition, labelling of scattered, small imma-
ture cells was observed in the upper cortical layers with
Tbr2 (layers II, III), Pax6 (layers I, II) (Fig. 4f), Cux1 and
ER81 (layer I) and Otx1 (layers I–VI). Co-localisation
between Cux1 and GFAP was observed in some cells.
Dysplasia adjacent to DNT
In the perilesional cortex of DNT with apparent dyslam-
ination in conventional stained sections (Table 1), CLM
patterns were as in controls, including labelling of white
matter neurons. Therefore, abnormal lamination was not
conﬁrmed. ER81 and Cux1 highlighted regions with
increased cellularity in layer I adjacent to the tumour
(Fig. 4g, i), in addition to the small intracortical hamartia-
like clusters of immature cells (Fig. 4g, h). No signiﬁcant
expression of Tbr1, Pax6, Map1b or MASH1 by these cells
was noted. Small numbers of immature and multipolar cells
Fig. 4 Temporal lobe sclerosis (TLS) and hippocampal sclerosis with
dysplasia and layer marker patterns within dysembryoplastic neuroep-
ithelial tumour (DNT) and the dysplasia in the adjacent cortex. a NeuN
TLS case illustrating neuronal loss from layers II and III and an
impression of hypercellularity and disorganisation in layer II. b Map1b
intense labelling of neurones in upper cortical layers (layer II) is
appreciated compared to deeper cortical layers in TLS case. c Tbr1
intense nuclear labelling of remaining, mature appearing neurones in
outer layer II was appreciated in some cases; a more horizontal
alignment of these neurones was noted in some regions in TLS.
d Map1b highlighted the abnormal orientation and clustering or
aggregation of neurones and entanglement of processes in layer II in
TLS. e Double labelling of Map1b and calretinin in layer II conﬁrmed
that the orientation of the calretinin radial processes was normal with
only selective misalignment or horizontal orientation of the Map1b
positivelayer IIcells in TLS.fPax6 frequent nuclearlabelling ofsmall
immature cells in the layer I/II was observed in TLS. g DNT H&E
staining of the perilesional cortex demonstrating hypercellularity in
layer I. Inset a cluster of immature cells with vesicular nuclei between
more mature neurones in the adjacent cortex which form a small
satellite nodule or hamartia (these were CD34 positive). h ER81
hamartia or satellite clusters of oligodendroglial like cells (OLC) were
stronglypositiveinDNT.iCux1thelayerIhypercellularity adjacentto
the DNT was highlighted with Cux1 with the majority of cells showing
nuclear positivity. j Map1b DNT tumour nodule in cortex highlighting
the pyramidal neurones suspended within the nodule that retain Map1b
positivity, normal morphology, orientation and laminar speciﬁc
distribution. k Map1b higher magniﬁcation of case shown in j. Bars
a, b 500 lm; b, j 20 lm; d, e 50 lm; f 10 lm; g, h, k 40 lm
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123were noted with Tbr2 (layers I, II), N200 and Otx1. Double
labelling with Otx1 and GFAP showed no co-localisation.
Within the tumour itself, oligodendrocyte-like cells were
ER81, and to lesser extent Cux1, positive but negative for
other markers; the astroglia component was negative. The
ﬂoating pyramidal neurons within the glioneuronal element
of the tumour or within cellular nodules showed layer-
appropriate expression of Tbr1, Map1b (Fig. 4j, k) or N200
in continuity with the adjacent cortex; this supported their
representing entrapped neurons.
Discussion
It is acknowledged that the diagnostic criteria FCD I are
less well deﬁned than FCD II [7, 41]. FCD I lacks the
distinctive and abnormal cell types that characterise FCD II
and usually they are not detected with in vivo MRI. Their
histological diagnosis is currently based on standard stains,
such as cresyl violet, for assessment of dyslamination and
likely includes heterogeneous pathologies. With lack of
speciﬁc markers there may be subjective interpretive bias
which probably explains the variation in diagnosing these
lesions between epilepsy centres and pathologists [12, 31,
38]. Consistently applied pathological criteria for FCD I
are desirable for reliable clinico-pathological and radio-
logical correlations to emerge, which can guide appropriate
surgical management and outcome prediction in these
patients.
CLM offer a potential for objective assessment of
developmental or acquired dyslamination and heterotopic
positioning of neurones. CLM have been more extensively
studied in experimental models than in humans. CLM are
developmentally, temporally and regionally regulated and
speciﬁc to different neuronal migratory pathways [26, 32,
36]. CLM expression, including cytoskeletal proteins and
transcription factors, are therefore likely to reﬂect both the
intrinsic properties of the cell as well as extrinsic factors
speciﬁc to locality [25]. Thus, any abnormal cellular
expression patterns in dysplasias, as well as diagnostic
value, might in theory provide additional information
regarding the timing of the insult and cell lineages involved.
In our selected CLM panel, layer speciﬁcity was shown
for Otx1, N200, Tbr1 and Map1b in keeping with previous
data [26, 46]. CLM have been most extensively studied for
layer V neurons [26, 35 for review] where diverse neuronal
subtypes are identiﬁed. ER81 selectively identiﬁes layer V
pyramidal neurons in rodent [37, 60] and primate cortex
[57] with low levels of expression reported in layers II/III
and VI [57, 60]. Although little studied in human brain
[26], in our cases ER81 showed no layer speciﬁcity, being
expressed in a proportion of pyramidal and non-pryamidal
neurons (and perineuronal satellite cells) through all layers.
Cux1, a putative marker of upper cortical layer neurones in
experimental models [39], showed pan-cortical staining,
with preferential labelling of layers II and IV and non-
pyramidal cell types in keeping with recent data demon-
strating expression in subsets of cortical interneurones
through all cortical layers [15]. One explanation for these
differences may be technical reasons, for example, different
methodologies (including antibody source) and different
ﬁxation and processing methods between experimental and
human tissues. However, it is also possible that CLM
expression patterns in experimental models are not always
replicated in human tissues.
Within dysplasia groups, relatively consistent abnor-
malities were identiﬁed with our CLM panel. The FCD I
series, with pathology as previously described [28], dem-
onstrated distinct populations of immature cells at the
interface of layers I and II with Otx1, Tbr1, and Pax6,
primarily in the younger patients. The localization and
morphology of these cells was reminiscent of those we
recently described in this pathology with doublecortin
immunohistochemistry [49]. Similar cells were not identi-
ﬁed in controls or other dysplasia types. In FCD I,
expansion of the distribution of Map1b-positive mature-
appearing neurons in outer cortex was noted, compared to
control patterns [14]. The persistent mini-columnar archi-
tecture seen on conventional stains was highlighted [28].
These features all suggest a delay in maturation and
organisation of upper cortical layers in this FCD I subtype.
FCD II is a well characterised malformation encoun-
tered in epilepsy surgical pathology with hallmark features
of DN and BC. The CLM patterns we observed were dis-
tinct from FCD I supporting the view that this is a different
biological entity. Although shared pathways for aberrant
neuronal–glial fate speciﬁcation for the abnormal cell types
in FCD II have been suggested [21], distinct immunopro-
ﬁles for DN and BC cells were shown with our broader
panel of antibodies. This could support origin from dif-
ferent migratory cell subsets during development. DN in all
layers, bar layer I, commonly expressed N200, Map1b and
Tbr1, albeit Tbr1 expression was weaker compared to
normal pyramidal cells. Map1b expression has been pre-
viously recognised in dysmorphic neurons in FCD [14].
Otx1 and Mash1 expression were less often observed in
dysmorphic neurones, as also noted in a previous study of
FCDIIB [32]. No labelling of DN with Tbr2 and Cux1 was
seen. The immunophenotype of DN therefore most closely
resembles that of mature cortical pyramidal projection
neurons [56], derived from intermediate progenitor cells
(IPCs), rather than from radial glial cell progenitors as
previously suggested [32]. IPCs are present throughout
corticogenesis, with developmentally regulated expression
of Pax6, Tbr2 and Tbr1 and produce neurons for all cortical
layers [30, 43]. It is proposed IPCs play a role in
Acta Neuropathol (2010) 120:517–528 525
123determination of laminar patterns, cortical thickness and
regional cyto-architectonics. Local disturbance of IPC
populations during the stages of cortical expansion could
conceivably be implicated in the causation of FCD IIB.
BC in FCDII showed CLM expression patterns distinct
from DN. Cytoplasmic positivity with Otx1 and Tbr2 and
nuclear labelling for Pax6, ER81 and Cux1 was shown.
The multipolar morphology of these abnormal cell types
has previously been demonstrated with immunohisto-
chemistry for GFAP-delta [34] CD34 [22], calbindin [52]
and doublecortin [49]. Increased Otx1 mRNA [6] and Pax6
expression [32] but variable Map1b expression [14, 21] has
previously been reported in BC, in keeping with our
observations. The striking Pax6/GFAP co-expression we
observed in BC supports their origin from radial glial cells
as previously proposed [10, 32]. A proliferative capacity of
BC has also been demonstrated [55], although many appear
to be arrested in G1 phase of the cell cycle [54]. Pax6
regulates exit from the cell cycle, controlling cortical cell
number [45]. It is conceivable therefore that the observed
sustained Pax6 expression in balloon cells also plays a role
in determining this cell cycle arrest.
Varied abnormalities in the temporal lobe and pole
adjacent to HS in patients with mesial temporal lobe
epilepsy have been described, including mild dysplasias
(previously called microdysgenesis) to FCD I [23, 53]. It is
debated whether these represent independent malformative
pathologies or re-organisational or dysmaturational chan-
ges linked with temporal lobe damage and HS [7]. One
distinct pattern, observed in the context of temporal lobe
sclerosis and HS, includes cytoarchitectural changes
involving layer II. Neuronal clustering and mal-orientation
may be extensive in layer II, although overlooked on
conventional stains [51]. We have shown that Map1b and
Tbr-1 highlights selective mal-orientation of neurones at
the interface of layer I and II. Calretinin-immunopositive
interneurones in this lamina, derived from tangential
migration [59], remained normally orientated. This speciﬁc
type of dysplasia, involving the last cortical layer to be
formed, may therefore be due to a relatively late event or
insult in the process of radial cortical migration, maturation
and organisation.
Dysplasias in the vicinity of DNTs are reported as an
added component in one-third [29] to 86% of cases [40].
The descriptions are principally cortical dyslamination [16,
18, 19, 29] corresponding to FCD I [41]. FCDII in asso-
ciation with DNT has been less often reported [47, 50]. The
perilesional cortex of DNT may be relevant to epilepto-
genesis [3, 4, 33] and the completeness of surgical
resection could potentially inﬂuence seizure outcome fol-
lowing surgery [40, 47, 50]. Correct classiﬁcation of this
dysplasia type and discrimination from tumour inﬁltration
zone is therefore desirable for accurate clinico-pathological
correlations.
Common features observed in conventional stains in our
DNT cases in the perilesional region included layer I
hypercellularity, impressions of dyslamination and satellite
clusters of immature cells (intracortical hamartias). CLM
studies, however, showed a normal laminar pattern in the
disrupted adjacent cortex. Furthermore, the pyramidal cells
within the glioneuronal elements and nodules of the tumour
displayed layer-appropriate expression, maturity and ori-
entation with Map1b, N200 and Tbr1 suggesting that they
are normal cortical neurones entrapped by the tumour. The
layer I hypercellularity and hamartias were highlighted by
ER81 and to a lesser extent Cux1, with cell phenotype
similar to tumour oligodendrocyte-like cells. These peri-
tumoural changes could represent either tumour extension
or precursor lesions from which the tumour arises, as
originally proposed [17], for example remnants of the
secondary germinal layers or marginal zone [13, 61].
Cortical changes adjacent to DNT are therefore distinct
from other FCD types. For perceived dyslamination on
H&E, CLM may aid in the distinction of true dysplasia
from peritumoural changes which will require veriﬁcation
through larger series. The mature neuronal component
within the glio-neuronal element are probably residual
entrapped cortical neurones.
In control cases we conﬁrmed variation in expression
patterns between neonatal and adult cortex for some CLM,
particularly Otx1 which showed strong labelling in cases
less than 1 year old. Otx1 does not inﬂuence early deter-
mination of neuronal cell type and laminar fate but has
later roles in maturation and organisation of superﬁcial
neurons as well as deeper cortical layers including of
GABAergic neurones [1, 42, 44, 48, 58]. We noted
increased expression of Otx 1 in small immature cells in
epilepsy cases, including those without dysplasia. CLM
also highlighted small, immature cell populations, for
example with Pax6 and Tbr2 in epilepsy cases, a proportion
co-expressing GFAP. These immature cell types may rep-
resent activation of residual progenitor cell populations or a
delay in normal rates of cell maturation. Recent studies
have conﬁrmed a physiological contribution of immature
neurones to seizures in FCD lesions [11]. Residual popu-
lations of multipotential cells in the maturing cortex may
switch to either glio-genic or neuronal pathways (including
GABAergic neurones) [25]. The regulation of this process
and diversiﬁcation of cell types may depend on develop-
mental stage, local factors and the maturing environment
[9, 25]. This process could conceivably be deregulated by
seizures. Therefore, the further delineation of immature
cell populations may be of relevance to our understanding
of the pathophysiology of dysplasias.
526 Acta Neuropathol (2010) 120:517–528
123In conclusion, this study highlights the potential appli-
cation of CLM to the conﬁrmation and categorization of
distinct dysplasia types and differentiation from normal
cortex. The spectrum of immature cell types highlighted
and their contribution to the pathophysiology of these
lesions deserves further study.
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